Program Overview

Approximately 20–25% of patients with gastric cancer have tumors which are HER2 positive. In this group, molecularly targeted therapy with trastuzumab added to cytotoxic chemotherapy improves overall survival and progression-free survival. However, accurate assessment of HER2 status requires adoption of specific guidelines for sample collection, testing, and scoring which vary from those recommended for breast cancer. This program will discuss how HER2 testing and HER2 targeted therapy should be incorporated into clinical care paradigms. This discussion will include the timing of sample collection, the methodology that should be adopted (IHC vs FISH), interpretation of results, and how these may be affected by the sample tested (biopsy vs resection). Two activities are offered on this website, a series of short slide/audio presentations and a downloadable monograph.

For those participants who also have an interest in breast cancer management, you may wish to access our parallel activity, either via this link, or using the button to the left.

Target Audience

The educational design of these activities addresses the needs of clinicians, pathologists, and nurses, involved in the treatment of patients with gastric cancer.

For information about the accreditation of this program

Please contact Global at Tel: (303) 395-1782 or


Date of Activity: September 2, 2011–September 2, 2012


This activity is jointly sponsored by Global Education Group and Strategic Consultants International

This activity is supported by an educational grant from Genentech.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Describe the efficacy of HER2 targeted therapy in gastric cancer
  • Evaluate methods for testing HER2 expression in gastric cancer, including type of specimen and required scoring standards
  • Identify how HER2 targeted therapy should be integrated into current management of gastric cancer.


William Gradishar Axel Grothey, MD - View Biography                             
Professor of Oncology
Consultant in the Division of Medical Oncology
The Mayo Clinic
Rochester, MN
Jeffrey Ross Jeffrey S. Ross, MD - View Biography
Cyrus Strong Merrill Professor and Chair
Department of Pathology and Laboratory Medicine
Albany Medical College
Albany, NY

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter

Reported Financial Relationship

Axel Grothey, MD

Grant/Research Support (awarded to Mayo Foundation)

Jeffrey S. Ross, MD

Consultant Independent Contractor
Foundation Medicine, Inc.
GenPath BRL
Speaker’s Bureau
Genentech, Inc.
Grant Research Support
Foundation Medicine, Inc.
Genentech, Inc.
Stock Shareholder
Foundation Medicine, Inc.
Syfr, Inc.
Various textbooks

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to this content of this CME activity:

Name of Planner or Manager

Reported Financial Relationship

Jackie Dawson, MSN

Nothing to disclose

Amanda Glazar, PhD

Nothing to disclose

Ian Morgan, MSc

Nothing to disclose